The funding round brings on board new investors including Temasek and the UK Sovereign AI Fund.

For privately held companies, Isomorphic’s raise is the second-largest in biotech history, surpassed only by Altos Labs’ $3 billion debut in 2022.

Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it might bring to the clinic.